Chris Brugger relapsed with Hodgkin's Lymphoma in December . 
  The 35-year-old must pay $16,000 every three weeks for non-taxpayer subsidised treatment Brentuximab Vedotin . 
  His 'My Name Is Chris' campaign and website was set up to raise money for the drug . 
  The treatment is not available on the Pharmaceutical Benefits Scheme (PBS) The Brugger family attended a Senate inquiry in Canberra on Monday . 
  Chris says the treatment has improved his condition dramatically . 
 